细胞因子诱导的杀伤细胞:异基因造血干细胞移植后过继细胞免疫治疗的独特平台。

IF 1.9 4区 医学 Q3 HEMATOLOGY
Transfusion Medicine and Hemotherapy Pub Date : 2024-09-24 eCollection Date: 2025-02-01 DOI:10.1159/000540964
Eva Rettinger
{"title":"细胞因子诱导的杀伤细胞:异基因造血干细胞移植后过继细胞免疫治疗的独特平台。","authors":"Eva Rettinger","doi":"10.1159/000540964","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Immunotherapies in general, and cellular immunotherapies, in particular are becoming increasingly integrated into current personalized cancer treatment, though still facing some obstacles in the allogeneic hematopoietic stem cell transplantation (HSCT) setting.</p><p><strong>Summary: </strong>The concept of isolating immune effector cells, expanding their numbers, enhancing their anticancer capabilities by modifying them without increasing their alloreactive potential is the mainstay of adoptive cellular immunotherapy after allogeneic HSCT. In this context, cytokine-induced killer (CIK) cells, a polyfunctional heterogenous population of conventional T cells, natural killer (NK) cells, and T-NK cells capable of using T cell and NK cell-like cytotoxicity mechanisms against a various cancers, showed minimal alloreactivity in pediatric and adult patients allografted for hematological malignancies. Furthermore, CIK cells have already shown compatibility with chemotherapy, different kinds of immune checkpoint inhibitors, epigenetic drugs, antibody-targeted therapies, and recently with chimeric antigen receptor-engineering techniques.</p><p><strong>Key messages: </strong>Hence, CIK cell therapy represents a unique platform for adoptive cell immunotherapies, guiding innovative treatment approaches from preclinical research to future clinical trials for cancer patients with yet unmet medical needs. In this context, the allogeneic HSCT setting provides an alternative source for safe and efficient adoptive allogeneic CIK cell strategies against a variety of cancers.</p>","PeriodicalId":23252,"journal":{"name":"Transfusion Medicine and Hemotherapy","volume":"52 1","pages":"77-95"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813276/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.\",\"authors\":\"Eva Rettinger\",\"doi\":\"10.1159/000540964\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Immunotherapies in general, and cellular immunotherapies, in particular are becoming increasingly integrated into current personalized cancer treatment, though still facing some obstacles in the allogeneic hematopoietic stem cell transplantation (HSCT) setting.</p><p><strong>Summary: </strong>The concept of isolating immune effector cells, expanding their numbers, enhancing their anticancer capabilities by modifying them without increasing their alloreactive potential is the mainstay of adoptive cellular immunotherapy after allogeneic HSCT. In this context, cytokine-induced killer (CIK) cells, a polyfunctional heterogenous population of conventional T cells, natural killer (NK) cells, and T-NK cells capable of using T cell and NK cell-like cytotoxicity mechanisms against a various cancers, showed minimal alloreactivity in pediatric and adult patients allografted for hematological malignancies. Furthermore, CIK cells have already shown compatibility with chemotherapy, different kinds of immune checkpoint inhibitors, epigenetic drugs, antibody-targeted therapies, and recently with chimeric antigen receptor-engineering techniques.</p><p><strong>Key messages: </strong>Hence, CIK cell therapy represents a unique platform for adoptive cell immunotherapies, guiding innovative treatment approaches from preclinical research to future clinical trials for cancer patients with yet unmet medical needs. In this context, the allogeneic HSCT setting provides an alternative source for safe and efficient adoptive allogeneic CIK cell strategies against a variety of cancers.</p>\",\"PeriodicalId\":23252,\"journal\":{\"name\":\"Transfusion Medicine and Hemotherapy\",\"volume\":\"52 1\",\"pages\":\"77-95\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813276/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transfusion Medicine and Hemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000540964\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion Medicine and Hemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540964","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:尽管同种异体造血干细胞移植(HSCT)仍面临一些障碍,但免疫疗法,尤其是细胞免疫疗法正越来越多地融入当前的个性化癌症治疗中。摘要:分离免疫效应细胞,增加它们的数量,通过修饰它们而不增加它们的同种异体造血干细胞移植后过继细胞免疫治疗的主要概念是在不增加它们的同种异体反应电位的情况下增强它们的抗癌能力。在这种情况下,细胞因子诱导的杀伤细胞(CIK)细胞,一种由传统T细胞、自然杀伤细胞(NK)细胞和T-NK细胞组成的多功能异质群体,能够利用T细胞和NK细胞样细胞毒性机制对抗各种癌症,在儿童和成人血液恶性肿瘤移植患者中显示出最小的同种异体反应性。此外,CIK细胞已经显示出与化疗、不同种类的免疫检查点抑制剂、表观遗传药物、抗体靶向治疗以及最近与嵌合抗原受体工程技术的相容性。因此,CIK细胞疗法代表了过继细胞免疫疗法的独特平台,为尚未满足医疗需求的癌症患者指导从临床前研究到未来临床试验的创新治疗方法。在这种情况下,同种异体造血干细胞移植设置提供了安全有效的过继同种异体CIK细胞策略对抗各种癌症的替代来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Cytokine-Induced Killer Cells: A Unique Platform for Adoptive Cell Immunotherapy after Allogeneic Hematopoietic Stem Cell Transplantation.

Background: Immunotherapies in general, and cellular immunotherapies, in particular are becoming increasingly integrated into current personalized cancer treatment, though still facing some obstacles in the allogeneic hematopoietic stem cell transplantation (HSCT) setting.

Summary: The concept of isolating immune effector cells, expanding their numbers, enhancing their anticancer capabilities by modifying them without increasing their alloreactive potential is the mainstay of adoptive cellular immunotherapy after allogeneic HSCT. In this context, cytokine-induced killer (CIK) cells, a polyfunctional heterogenous population of conventional T cells, natural killer (NK) cells, and T-NK cells capable of using T cell and NK cell-like cytotoxicity mechanisms against a various cancers, showed minimal alloreactivity in pediatric and adult patients allografted for hematological malignancies. Furthermore, CIK cells have already shown compatibility with chemotherapy, different kinds of immune checkpoint inhibitors, epigenetic drugs, antibody-targeted therapies, and recently with chimeric antigen receptor-engineering techniques.

Key messages: Hence, CIK cell therapy represents a unique platform for adoptive cell immunotherapies, guiding innovative treatment approaches from preclinical research to future clinical trials for cancer patients with yet unmet medical needs. In this context, the allogeneic HSCT setting provides an alternative source for safe and efficient adoptive allogeneic CIK cell strategies against a variety of cancers.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.00
自引率
9.10%
发文量
47
审稿时长
6-12 weeks
期刊介绍: This journal is devoted to all areas of transfusion medicine. These include the quality and security of blood products, therapy with blood components and plasma derivatives, transfusion-related questions in transplantation, stem cell manipulation, therapeutic and diagnostic problems of homeostasis, immuno-hematological investigations, and legal aspects of the production of blood products as well as hemotherapy. Both comprehensive reviews and primary publications that detail the newest work in transfusion medicine and hemotherapy promote the international exchange of knowledge within these disciplines. Consistent with this goal, continuing clinical education is also specifically addressed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信